Exploiting the Achilles' heel of cancer: disrupting glutamine metabolism for effective cancer treatment
Open accessThe DOI matches its Crossref record; 264 of the 264 references it cites were found in a registry or an index.
Abstract
Cancer cells have adapted to rapid tumor growth and evade immune attack by reprogramming their metabolic pathways. Glutamine is an important nitrogen resource for synthesizing amino acids and nucleotides and an important carbon source in the tricarboxylic acid (TCA) cycle and lipid biosynthesis pathway. In this review, we summarize the significant role of glutamine metabolism in tumor development and highlight the vulnerabilities of targeting glutamine metabolism for effective therapy. In particular, we review the reported drugs targeting glutaminase and glutamine uptake for efficient cancer treatment. Moreover, we discuss the current clinical test about targeting glutamine metabolism and the prospective direction of drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, despite promising results in preclinical and early clinical trials, their clinical effectiveness is often compromised by resistance mechanisms due to tumor heterogeneity and metabolic plasticity, as well as toxicity to normal tissue [63].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [63]
The cited source says what the claim attributes to it.
In the citing paper
“Targeting the glutamine dependency of cancer cells is a promising therapeutic strategy for cancer and many agents targeting various steps of glutamine metabolism are currently in development [63].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233 · cited 1×
“For example, cancer cells produce lactate through glycolysis to satisfy their energy needs even in the presence of oxygen, known as the Warburg effect (Ward and Thompson, 2012).”
BackgroundMetabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
From Krebs to clinic: glutamine metabolism to cancer therapy
Altman, B. J., Stine, Z. E., & Dang, C. V. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.71 · Cited by 2,119
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990 · cited 3×
“In addition, the intracellular glutamine can maintain redox homeostasis through many sophisticated mechanisms (Son et al., 2013; Koppula et al., 2018; Jaganjac et al., 2020; Ying et al., 2021).”
BackgroundCancer metabolism: looking forward
Martínez-Reyes, I., & Chandel, N. S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00378-6 · Cited by 1,824
Research works printed but not linked: 1
- Mickle M. (2022). VGLL4 and glutamine deprivation suppress YAP1/TEAD signaling to attenuate the SCC cancer phenotype. Baltimore: University of Maryland.
Cited by
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Role of monocarboxylate transporters in cancer immunology and their therapeutic potential
Faghihkhorasani, F., Moosavi, M., Abdulwahid, A. R. R., Kavei, M., Karimi, S., Karimi, M. S., Vezvaei, P., Varkiani, M. M., Aref, A. R., & Ebrahimi, N. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70110 · Cited by 27
Li, Y., Lu, Y., Lü, W., Zhong, N., Li, N., Xu, Z., Zhang, J., Sun, H., Wu, F., Teng, Z., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113739 · Cited by 21
Lin, Z., Chang, C., Zhao, S., Fang, L., & Wang, P. (2025) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2025.0115 · Cited by 28
Deciphering the landscape of allosteric glutaminase 1 inhibitors as anticancer agents
Vagaggini, C., D’Ursi, P., Poggialini, F., Fossa, P., Francesconi, V., Trombetti, G., Orro, A., Dreassi, E., Schenone, S., Tonelli, M., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108523 · Cited by 18
The Overlapping Biology of Sepsis and Cancer and Therapeutic Implications
Tripathi, A. K., & Srivastava, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13061280 · Cited by 12
Computational modeling of cancer cell metabolism along the catabolic-anabolic axes
Castrejon, J. V., Levine, H., Kaipparettu, B. A., Onuchic, J. N., George, J. T., & Jia, D. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00525-x · Cited by 12
The emerging role of metabolic interventions in uveal melanoma
Kuranaga, Y., Hatem, Y., Grossniklaus, H. E., Ali, S. S., & Meir, E. G. V. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.10.002 · Cited by 10
A hormetic response model for glutamine stress in cancer
Grenier, S. F., & Commisso, C. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.11.008 · Cited by 8
Zhang, C., Han, Y., Yao, W., Hong, Q., & Chen, N. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5684 · Cited by 8
Voor, S. F., Cooper, A. J. L., & Pinto, J. T. (2025) · Analytical Biochemistry · doi:10.1016/j.ab.2025.115989 · Cited by 6
Metabolic Signature of FLT3-Mutated AML: Clinical and Therapeutic Implications
Banella, C., Catalano, G., Calvani, M., Candi, E., Noguera, N. I., & Travaglini, S. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15090431 · Cited by 6
Dahan, P., Maillet, T. M., Malric, L., Delmas, C., Lubrano, V., Martinez-Gala, J., Flandin, G., Aboudaram, A., Héliès‐Toussaint, C., Skuli, N., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02161-2 · Cited by 5
Sun, Y., Cui, Y., Luo, D., & Tian, C. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11309-1 · Cited by 5
Targeted mitochondrial metabolism for anti-tumor therapy
Yan, C., Li, X., Pei, W., Zhang, X., Wang, H., Chen, Z., Lin, F., & Lu, G. (2025) · Mitochondrion · doi:10.1016/j.mito.2025.102073 · Cited by 4
Zhuang, H., Hang, L., Ren, X., Huang, L., Wu, Q., Guo, W., Chen, Z., Shimei, L., Liu, N., Fu, C., et al. (2025) · Small · doi:10.1002/smll.202510541 · Cited by 4
Fan, X., Guo, S., Li, W. W., Wang, Y., Bao, J., He, J., & Jin, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1740644 · Cited by 5
Fueling the Fire: How Glutamine Metabolism Sustains Leukemia Growth and Resistance
Silvestri, G. (2026) · BioMed · doi:10.3390/biomed6010007 · Cited by 5
Nie, J., Liu, X., Xu, M., Gu, X., Hu, S., Sun, H., Zhou, L., Xu, T., Pan, Y., & Wang, S. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101287 · Cited by 4
Drug Repurposing: A Conduit to Unravelling Metabolic Reprogramming for Cancer Treatment
Chaudhary, S., Rana, A., & Bhatnagar, S. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575339660250106093738 · Cited by 3
The Redox Paradox of Natural Supplements in Cancer: A Narrative Review to Guide Clinical Practice
Martinez, P., Martínez, E. M., Gillot, L., Makis, W., Peavler, C., Vega‐Gálvez, A., Joulia, F., & Grant, W. B. (2026) · Antioxidants · doi:10.3390/antiox15070809 · Cited by 3
Metabolic hallmarks of trastuzumab resistance
Martín-Castillo, B., Verdura, S., Llop‐Hernández, À., Lupu, R., Cuyàs, E., & Menéndez, J. A. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2532394 · Cited by 3
Dai, Y., Zhang, L., Wang, T., Liu, H., Yang, W., & Wang, H. (2025) · Human Genomics · doi:10.1186/s40246-025-00881-z · Cited by 2
Onyia, A. F., Olasehinde, O. E., Shagaya, U. N., Nwachukwu, E., Oyekan, A. O., Fatiregun, O. A. A., Olatunji, T. A., Lawal, A., Alabi, A. A., Aje, E. A., et al. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00965 · Cited by 2
Wang, C., Feng, Q., Lu, H., He, Q., Zhang, P., Tang, J., Liu, Z., Liu, J., & Chen, B. (2024) · Materials Today Nano · doi:10.1016/j.mtnano.2024.100509 · Cited by 3
Pinto, S., Andrade, N., Carmo, F., Silva, C., & Martel, F. (2025) · PharmaNutrition · doi:10.1016/j.phanu.2025.100432 · Cited by 2
Emerging roles of the chromatin remodeler MORC2 in cancer metabolism
Mohapatra, B., & Pakala, S. B. (2024) · Medical Oncology · doi:10.1007/s12032-024-02464-9 · Cited by 1
Tatar, C., & Erdemir, A. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107499 · Cited by 1
Yang, S., Ko, M., Zhang, W., & Jeong, S. M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.153134 · Cited by 2
Glutamine Metabolism: Role in Cancer Cell Proliferation and Survival
Chakraborty, A. J., Pramanik, S., Mullick, S., Nath, R., Mondal, M., Pal, R., Ashique, S., & Jana, M. (2026) · Cancer treatment and research · doi:10.1007/978-3-032-21861-2_3 · Cited by 1
Metabolic plasticity in the pancreatic cancer metastatic cascade
Zhu, B., Guo, Y., & Lu, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189622 · Cited by 1
Aftab, A., Pontoriero, M., Chimia, M. L., Gallelli, L., & Scumaci, D. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03150-1 · Cited by 1
Knockdown of GRK5 induces mitochondrial hyperpolarization in porcine embryos
Kim, J.-D., Lee, S., Lu, Q., Zhan, C., Lee, G.-H., Sim, J.-M., Song, H.-J., Choi, J., & Cui, X. (2025) · Reproduction · doi:10.1530/rep-25-0052
Cancer metabolism: bridging tumorigenesis mechanisms to treatment susceptibility
Liu, J., Shan, D., Zhou, Z., Wen, X., Fu, R., Xu, B., Luo, P., Li, Z., & Zhang, L. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04052-3
Self-citationIntegrating 3D Tumor Models and Microfluidics for Precise Metabolic ControlPreprint
Bastien, E., Diallo, A., Mercury, M., Cappello, J. Y., Delanoë‐Ayari, H., & Rivière, C. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.07.698130
Metabolic adaptation of human glioblastoma cells to doxorubicin-induced chemotherapeutic stress
Pudełek, M. (2026) · Homo Politicus (Academy of Humanities and Economics in Lodz)
Glutamine metabolic enzymes: to filament or not to filament?
Machado, R. A. C., Silva, I. R. E., Fontes-Milz, T., Chang-Halabi, Y., Vargas, J. A., Ambrosio, A. L. B., & Dias, S. M. G. (2026) · Biochemical Society Transactions · doi:10.1042/bst20253136
Viswanathan, T., Devadoss, D., Nagaraj, A., Rosen, B. P., Chand, H. S., & Venkadesh, S. (2026) · Biomedicines · doi:10.3390/biomedicines14051100
Bindi, G. (n.d.) · BOA (University of Milano-Bicocca)
Wang, S. Z., Mu, J., Zhao, W., Hu, C., Shi, X., Zhou, H., Liu, J., & Wu, F. (2026) · Aging Cell · doi:10.1111/acel.70592
Role of molecular target therapies in effective breast cancer treatments
Ghosh, B., Shil, S., & Kumavath, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43846-2.00017-9
Wei, J., Yamada, Y., Tamura, T., Sugiura, M., Zhao, X., Ni, M., Aierken, A., Sazuka, T., Imamura, Y., & Sakamoto, S. (2026) · Cancer Science · doi:10.1111/cas.70437
Wang, J., Wang, J., Tian, J., & Gao, P. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01466-4
Glutamine metabolism in health and disease
Zhao, J., Lin, Y., Gao, R., Gao, H., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02981-1
Self-citationWijaya, M. D., Indraningrat, A. A. G., Nafisah, W., & Ertanti, N. (2026) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3515
Metadata
- Authors
- Fan, Y., Xue, H., Li, Z., Huo, M., Gao, H., & Guan, X.
- Affiliations
- Beihua University (CN)
- Taizhou University (CN)
- Corresponding author
- Gao, Hongxia
- Guan, Xingang
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2024-03-06
- Volume
- 15
- Pages
- 1345522-1345522
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10952006
- OpenAlex
- W4392517467
- Cited by
- 40
- References
- 263
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 3
- FWCI
- 1.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China
- Beihua University
- Science and Technology Plan Project of Taizhou (22gya03)
- Natural Science Foundation of Zhejiang Province (LY23C100001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- glutamine metabolism, cancer metabolism, glutaminase inhibitors, tumor metabolic reprogramming, TCA cycle, lipogenesis, cancer therapy, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.